

Cee, Russia & Cis Retinal Biologics Market Research Report Forecast to 2030

Market Report | 2023-07-06 | 97 pages | Market Research Future

AVAILABLE LICENSES:

- Single User Price \$2950.00
- Enterprisewide Price \$5250.00

Report description:

Cee, Russia & Cis Retinal Biologics Market Research Report Forecast to 2030

Market Overview

The growth of the CEE, Russia & CIS retinal biologics market is attributed to the rising R&D activities in retinal gene therapies, rising efforts for the development of retinal drugs, increasing adoption of retinal biologics for macular degeneration treatment, and increasing prevalence of chronic retinal diseases. However, regulatory obstructions, concerns pertaining to the adverse effects of biologic treatment, and initial high capital investment might hamper the market's growth in the forecast period. Retinal biologics are drugs that are derived from living organisms or may contain derivatives from living organisms to treat a wide range of retinal disorders. Human eyes are highly delicate and can be affected by the minutest of things. Therefore, its security is of high importance. People across the globe are facing some serious retinal health disorders including diabetic retinopathy, infectious retinitis, age-related macular degeneration, macular edema, retinoblastoma, uveitis, retinal degeneration, retinoschisis, and macular hole.

However, the market is being held back by a lack of retinal biologics, dangerous biologic side effects, and limited access to retinal biologics and efficient treatments due to higher costs. Moreover, the market is being challenged by retinal biologics' side effects, which include retinal tears, sickness, and eye pain. The strict regulatory compliances associated with biologics approval imposed by governing authorities are impeding industry growth.

The growing geriatric population and associated diseases such as age-related macular degeneration (AMD) will be a driving factor in this market's growth. Furthermore, increased smoking and alcohol consumption creates several health issues, including diseases such as hypertension and hypercholesterolemia, which damages retinal vessels eventually will benefit the retinal biologics industry. For instance, according to Eurostat Statistics in 2019, Bulgaria recorded 28.7% consumes tobacco in the form of smoking on a daily basis. Moreover, according to the State Agency for the Prevention of Alcohol-Related Problems (PARPA), alcohol consumption increased by 0.23 liter per capita 2019 from 2018.

Market Segmentation

CEE, Russia & CIS retinal biologics market is classified into drug type, distribution channel, indication, and region. Major Players

The key market players are F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Bayer AG, and

Scotts International. EU Vat number: PL 6772247784

Table of Contents:

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 11

- 1.1 OVERVIEW 11
- 2∏MARKET INTRODUCTION∏12
- 2.1 □ DEFINITION □ 12
- 2.2 SCOPE OF THE STUDY 12
- 2.3 RESEARCH OBJECTIVE 12
- 2.4□MARKET STRUCTURE□13
- 2.5 ASSUMPTIONS & LIMITATIONS 13
- 3 RESEARCH METHODOLOGY 14
- 3.1 DATA MINING 14
- 3.2 SECONDARY RESEARCH 15
- 3.3 PRIMARY RESEARCH 16
- 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 17
- 3.5 FORECASTING TECHNIQUES 18
- 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 19
- 3.6.1 BOTTOM-UP APPROACH 19
- 3.6.2 TOP-DOWN APPROACH 20
- 3.7 DATA TRIANGULATION 20
- 3.8 VALIDATION 21
- 4∏MARKET DYNAMICS∏22
- 4.1.1 ANALYSTS' COMMENTS 23
- 5 MARKET FACTOR ANALYSIS 25
- 5.1 □ VALUE CHAIN ANALYSIS □ 25
- 5.1.1 R&D 26
- 5.1.2 MANUFACTURING 26
- 5.1.3 DISTRIBUTION & SALES □ 26
- 5.1.4 POST-SALES MONITORING 26
- 5.2 PORTER'S FIVE FORCES MODEL 27
- 5.2.1 THREAT OF NEW ENTRANTS 27
- 5.2.2 BARGAINING POWER OF SUPPLIERS 27
- 5.2.3 THREAT OF SUBSTITUTES 28
- 5.2.4 BARGAINING POWER OF BUYERS 28
- 5.2.5 INTENSITY OF RIVALRY 28
- 5.3 IMPACT OF COVID-19 ON THE CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET 28
- 5.3.1 IMPACT ON SUPPLY CHAIN 28
- 5.3.2 IMPACT ON PRODUCTION 29
- 5.3.3 IMPACT ON MARKET PLAYERS 29
- 6□CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DRUG CLASS□30
- 6.1□OVERVIEW□30
- 6.2□TNF-? INHIBITOR□31

Scotts International. EU Vat number: PL 6772247784

6.3 UEGF-A ANTAGONIST 32

7 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY INDICATION 33

7.1 OVERVIEW 33

7.2 MACULAR DEGENERATION 35

7.3 DIABETIC RETINOPATHY 35

7.4 RETINITIS PIGMENTOSA DISEASE 36

7.5 UVEITIS 36

7.6□OTHERS□36

8 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL 37

8.1∏OVERVIEW∏37

8.2∏HOSPITALS AND CLINICS∏39

8.3∏PHARMACIES∏39

8.4∏OTHERS∏39

9∏CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY REGION∏41

9.1 CEE COUNTRIES 43

9.1.1 □ POLAND □ 45

9.1.2□CZECH REPUBLIC□46

9.1.3 BULGARIA 47

9.1.4 HUNGARY 49

9.1.5 | ROMANIA | 50

9.1.6 REST OF CEE COUNTRIES 52

9.2 RUSSIA 53

9.3∏CIS COUNTRIES∏55

9.3.1 KAZAKHSTAN 57

9.3.2∏BELARUS∏58

9.3.3 | ARMENIA | 59

9.3.4∏UZBEKISTAN∏60

9.3.5 UKRAINE 061

9.3.6 REST OF CIS COUNTRIES 62

10 COMPETITIVE LANDSCAPE 64

10.1 OVERVIEW 64

10.2 COMPETITIVE BENCHMARKING 65

10.3 \square KEY DEVELOPMENTS & GROWTH STRATEGIES \square 66

10.3.1 PRODUCT LAUNCHES/PRODUCT APPROVALS 66

10.4□FINANCIAL MATRIX□66

10.4.1 SALES (USD MILLION), 2021 66

10.4.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021 67

11 COMPANY PROFILES 68

11.1□AMGEN INC.□68

11.1.1 COMPANY OVERVIEW 68

11.1.2 FINANCIAL OVERVIEW 69

11.1.3 PRODUCTS OFFERED 69

11.1.4 KEY DEVELOPMENTS 69

11.1.5 SWOT ANALYSIS 70

11.1.6 KEY STRATEGIES 70

11.2 NOVARTIS AG 71

11.2.1 COMPANY OVERVIEWS 71

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.2.2 FINANCIAL OVERVIEW 72
- 11.2.3 PRODUCTS OFFERED 73
- 11.2.4 KEY DEVELOPMENTS 73
- 11.2.5 SWOT ANALYSIS 73
- 11.2.6 KEY STRATEGIES 74
- 11.3 SAMSUNG BIOEPIS CO., LTD 75
- 11.3.1 COMPANY OVERVIEWS 75
- 11.3.2 FINANCIAL OVERVIEW 76
- 11.3.3 PRODUCTS OFFERED 76
- 11.3.4 KEY DEVELOPMENTS 77
- 11.3.5 KEY STRATEGIES 77
- 11.4∏INTAS PHARMACEUTICALS LTD. ∏78
- 11.4.1□COMPANY OVERVIEW□78
- 11.4.2 FINANCIAL OVERVIEW 78
- 11.4.3 PRODUCTS OFFERED 78
- 11.4.4 □KEY DEVELOPMENTS □ 78
- 11.4.5 SWOT ANALYSIS 79
- 11.4.6 KEY STRATEGIES 79
- 11.5□ABBVIE INC.□80
- 11.5.1□COMPANY OVERVIEW□80
- 11.5.2 FINANCIAL OVERVIEW 81
- 11.5.3 PRODUCTS OFFERED 81
- 11.5.4 | KEY DEVELOPMENTS | 82
- 11.5.5 KEY STRATEGIES 82
- 11.6 ALIMERA SCIENCES 83
- 11.6.1 COMPANY OVERVIEW 83
- 11.6.2 FINANCIAL OVERVIEW 83
- 11.6.3 PRODUCTS OFFERED 84
- 11.6.4 KEY DEVELOPMENTS 84
- 11.6.5 KEY STRATEGIES 84
- 11.7□BAYER AG□85
- 11.7.1 COMPANY OVERVIEWS 85
- 11.7.2∏FINANCIAL OVERVIEW∏86
- 11.7.3 PRODUCTS OFFERED 86
- 11.7.4 KEY DEVELOPMENTS 87
- 11.7.5□SWOT ANALYSIS□87
- 11.7.6 KEY STRATEGIES 87
- 11.8 POLPHARMA BIOLOGICS GROUP 88
- 11.8.1 COMPANY OVERVIEW 88
- 11.8.2 FINANCIAL OVERVIEW 88
- 11.8.3 PRODUCTS OFFERED 88
- 11.8.4 KEY DEVELOPMENTS 88
- 11.8.5 KEY STRATEGIES 88
- 11.9 SUN PHARMACEUTICAL INDUSTRIES LTD. 89
- 11.9.1 COMPANY OVERVIEW 89
- 11.9.2∏FINANCIAL OVERVIEW∏90
- 11.9.3 PRODUCTS OFFERED 90

Scotts International. EU Vat number: PL 6772247784

11.9.4 KEY DEVELOPMENTS 91

11.9.5 KEY STRATEGIES 91

11.10 F. HOFFMANN-LA ROCHE LTD 92

11.10.1 COMPANY OVERVIEW 92

11.10.2 FINANCIAL OVERVIEW 93

11.10.3 PRODUCTS OFFERED 93

11.10.4 KEY DEVELOPMENTS 93

11.10.5 SWOT ANALYSIS 94

11.10.6 KEY STRATEGIES 94

12

APPENDIX

95

12.1 REFERENCES 95

12.2 RELATED REPORTS 96

?



Print this form

To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

Cee, Russia & Cis Retinal Biologics Market Research Report Forecast to 2030

Market Report | 2023-07-06 | 97 pages | Market Research Future

	Single User Price Enterprisewide Price			+2050.00
	Enterprisowide Price			\$2950.00
	Litterprisewide Frice			\$5250.00
			VAT	
			Total	
lease circle the relevan	t license option. For any questions ple	ease contact support@sc	otts-international.com or 0048 603 39	94 346.
** VAT will be added at 2	23% for Polish based companies, indiv	riduals and EU based con	npanies who are unable to provide a	valid EU Va
		DI di		
mail*		Phone*		
irst Name*		Last Name*		
ob title*				
Company Name*		EU Vat / Tax ID / Ni	IP number*	
ddress*		City*		
Zip Code*		Country*		
		Date	2025-05-07	
		Signature		\neg
		Signature		